实用临床医药杂志2013，Vol.17Issue(3)：12-15,4.DOI:10.7619/jcmp.201303004
非小细胞肺癌β-微管蛋白Ⅲ表达及其与含紫杉醇方案耐药的关系
Relationship between β-tubulin Ⅲ expression and paclitaxel-containing regimen with drug resistance in non small-cell lung cancer
摘要
Abstract
Objective To determine the relationship between the expression of β-tubulin M and paclitaxel-containing regimen with drug resistance in non small-cell lung cancer ( NSCLC ). Methods A total of 120 NSCLC patients were randomly divided into two groups. The treatment group (60 cases) was treated with TP regimen, the control group (60 cases) with NP regimen. All patients had received 2 cycles chemotherapy. The β-tubulin Ⅲ expression of 108 NSCLC patients were examined via immunohistochemical method and the relationship between the β-tubulin Ⅲ expression and paclitaxel-containing regimen with drug resistance were analyzed. Results β-tubulin Ⅲ expression level did not show any association with patient age, sex, clinical stage and histology type. The expression of β-tubulin Ⅲ was associated with paclitaxel resistance in NSCLC. The high expression rate of β-tubulin Ⅲ in chemo-resistant patients was 77.3% , and that of chemo-sensitive patients was 42.1% . The expression of β-tubulin Ⅲ was not associated with vinorelbine resistance in NSCLC. Conclusion The expression of β-tubulin Ⅲ in NSCLC is related to paclitaxel-containing regimen resistance, which shows predictive value to chemoresistance in NSCLC.关键词
非小细胞肺癌/β-微管蛋白Ⅲ/紫杉醇/耐药Key words
non small-cell lung cancer/ β-tubulin Ⅲ/ paclitaxel/ drug resistance分类
医药卫生引用本文复制引用
刘萍,王豪勋,王海莉..非小细胞肺癌β-微管蛋白Ⅲ表达及其与含紫杉醇方案耐药的关系[J].实用临床医药杂志,2013,17(3):12-15,4.基金项目
中国高校医学期刊临床专项资金(11220261) （11220261）
